Skip to main content
. Author manuscript; available in PMC: 2022 May 11.
Published in final edited form as: Nat Cancer. 2021 Nov 11;2(11):1170–1184. doi: 10.1038/s43018-021-00262-0

Extended Data Fig. 2. |. LILRB3 increases the survival of monocytic AML cells against cytotoxic T cells.

Extended Data Fig. 2. |

a, Percentages of CD4 and CD8 T cells in spleens of mice injected with mouse IgG or anti-mCD8 (10 mg/kg). b, CFU assays (MethoCult™ GF M3434) of regular BM cells mixed with mouse T cells specific to MLL-AF9 AML cells (T-AF9) or non-specific T cells (T-LPS) (n=3 independent cell cultures). c, Expression of INFγ,TNFα, and PD-1 on CD4 and CD8 T cells from spleens of mice engrafted with MLL-AF9 AML cells expressing LILRB3 FL or LILRB3 with intracellular domain truncation.